PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy

Journal of Proteome Research

Volumn 13, Issue 11, 2014, Pages 4970-4982

  Musiani, Daniele ^a,b,c   Hammond, Dean E ^c,d   Cirillo, Luca ^a,b   Erriquez, Jessica ^b   Olivero, Martina ^a,b   Clague, Michael J ^c   Di Renzo, Maria Flavia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

ovarian cancer; PIM2 kinase; platinum drugs; SILAC phosphoproteomics

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 2; DNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PIM2 KINASE; PROTEIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BAD PROTEIN, HUMAN; ONCOPROTEIN; PIM2 PROTEIN, HUMAN; PROTEIN BAD; PROTEIN SERINE THREONINE KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL; CELL GROWTH; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; RNA INTERFERENCE; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROCEDURES; PROTEIN MOTIF; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; HUMANS; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 84908868699     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500651n     Document Type: Article

References (46)

1. Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Eur. J. Cancer 1998, 34, 1522-34
2. Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 1999, 99, 2467-98
3. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance Oncogene 2012, 31, 1869-83
4. Bartek, J.; Lukas, J. DNA damage checkpoints: from initiation to recovery or adaptation Curr. Opin. Cell Biol. 2007, 19, 238-45
5. Pines, A.; Kelstrup, C. D.; Vrouwe, M. G.; Puigvert, J. C.; Typas, D.; Misovic, B.; de Groot, A.; von Stechow, L.; van de Water, B.; Danen, E. H.; Vrieling, H.; Mullenders, L. H.; Olsen, J. V. Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells Mol. Cell. Biol. 2011, 31, 4964-77
6. Reinhardt, H. C.; Yaffe, M. B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2 Curr. Opin. Cell Biol. 2009, 21, 245-55
7. Omerovic, J.; Hammond, D. E.; Prior, I. A.; Clague, M. J. Global snapshot of the influence of endocytosis upon EGF receptor signaling output J. Proteome Res. 2012, 11, 5157-66
8. Wis̈niewski, J. R.; Zougman, A.; Nagaraj, N.; Mann, M. Universal sample preparation method for proteome analysis Nat. Methods 2009, 6, 359-62
9. Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.; Mortensen, P.; Mann, M. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks Cell 2006, 127, 635-48
10. Cox, J.; Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J. V.; Mann, M. Andromeda: a peptide search engine integrated into the MaxQuant environment J. Proteome Res. 2011, 10, 1794-805
11. Cox, J.; Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 2008, 26, 1367-72
12. Rigbolt, K. T.; Vanselow, J. T.; Blagoev, B. GProX, a user-friendly platform for bioinformatics analysis and visualization of quantitative proteomics data Mol. Cell. Proteomics 2011, 10, O110.007450
13. Futschik, M. E.; Carlisle, B. Noise-robust soft clustering of gene expression time-course data J. Bioinf. Comput. Biol. 2005, 3, 965-88
14. Rigbolt, K. T.; Prokhorova, T. A.; Akimov, V.; Henningsen, J.; Johansen, P. T.; Kratchmarova, I.; Kassem, M.; Mann, M.; Olsen, J. V.; Blagoev, B. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation Sci. Signaling 2011, 4, rs3
15. Schwartz, D.; Gygi, S. P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets Nat. Biotechnol. 2005, 23, 1391-8
16. Linding, R.; Jensen, L. J.; Pasculescu, A.; Olhovsky, M.; Colwill, K.; Bork, P.; Yaffe, M. B.; Pawson, T. NetworKIN: a resource for exploring cellular phosphorylation networks Nucleic Acids Res. 2008, 36, D695-9
17. Coltella, N.; Rasola, A.; Nano, E.; Bardella, C.; Fassetta, M.; Filigheddu, N.; Graziani, A.; Comoglio, P. M.; Di Renzo, M. F. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis Int. J. Cancer. 2006, 118, 2981-90
18. Bardella, C.; Dettori, D.; Olivero, M.; Coltella, N.; Mazzone, M.; Di Renzo, M. F. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo Clin. Cancer Res. 2007, 13, 2191-8
19. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B. E.; Sumer, S. O.; Aksoy, B. A.; Jacobsen, A.; Byrne, C. J.; Heuer, M. L.; Larsson, E.; Antipin, Y.; Reva, B.; Goldberg, A. P.; Sander, C.; Schultz, N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discovery 2012, 2, 401-4
20. Choudhary, C.; Mann, M. Decoding signalling networks by mass spectrometry-based proteomics Nat. Rev. Mol. Cell Biol. 2010, 11, 427-39
21. Xiang, Y.; Ma, N.; Wang, D.; Zhang, Y.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Zhang, G.; Gao, X. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine Oncogene 2013, 33, 378-86
22. Zhang, X.; Samadi, A. K.; Roby, K. F.; Timmermann, B.; Cohen, M. S. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A Gynecol. Oncol. 2012, 124, 606-12
23. Rasola, A.; Anguissola, S.; Ferrero, N.; Gramaglia, D.; Maffe, A.; Maggiora, P.; Comoglio, P. M.; Di Renzo, M. F. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin Cancer Res. 2004, 64, 1744-50
24. Hu, C.; Zhang, S.; Gao, X.; Xu, X.; Lv, Y.; Zhang, Y.; Zhu, Z.; Zhang, C.; Li, Q.; Wong, J.; Cui, Y.; Zhang, W.; Ma, L.; Wang, C. Roles of kruppel-associated box (KRAB)-associated co-repressor KAP1 Ser-473 phosphorylation in DNA damage response J. Biol. Chem. 2012, 287, 18937-52
25. Johnson, L. N.; Noble, M. E.; Owen, D. J. Active and inactive protein kinases: structural basis for regulation Cell 1996, 85, 149-58
26. Pegram, M. D.; Lipton, A.; Hayes, D. F.; Weber, B. L.; Baselga, J. M.; Tripathy, D.; Baly, D.; Baughman, S. A.; Twaddell, T.; Glaspy, J. A.; Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 1998, 16, 2659-71
27. Price, P. M.; Yu, F.; Kaldis, P.; Aleem, E.; Nowak, G.; Safirstein, R. L.; Megyesi, J. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2 J. Am. Soc. Nephrol. 2006, 17, 2434-42
28. Xia, Y.; Yang, W.; Bu, W.; Ji, H.; Zhao, X.; Zheng, Y.; Lin, X.; Li, Y.; Lu, Z. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells J. Biol. Chem. 2013, 288, 19321-9
29. Blanco-Aparicio, C.; Carnero, A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities Biochem. Pharmacol. 2013, 85, 629-43
30. Nawijn, M. C.; Alendar, A.; Berns, A. For better or for worse: the role of Pim oncogenes in tumorigenesis Nat. Rev. Cancer 2011, 11, 23-34
31. Chen, L. S.; Redkar, S.; Bearss, D.; Wierda, W. G.; Gandhi, V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Blood 2009, 114, 4150-7
32. Chang, M.; Kanwar, N.; Feng, E.; Siu, A.; Liu, X.; Ma, D.; Jongstra, J. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation Mol. Cancer Ther. 2010, 9, 2478-87
33. Zhang, Y.; Wang, Z.; Li, X.; Magnuson, N. S. Pim kinase-dependent inhibition of c-Myc degradation Oncogene 2008, 27, 4809-19
34. Zippo, A.; De Robertis, A.; Serafini, R.; Oliviero, S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation Nat. Cell Biol. 2007, 9, 932-44
35. Network, C. G. A. R. Integrated genomic analyses of ovarian carcinoma Nature 2011, 474, 609-15
36. Takahashi, A.; Ohnishi, T. Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett. 2005, 229, 171-9
37. Brozovic, A.; Osmak, M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance Cancer Lett. 2007, 251, 1-16
38. Reinhardt, H. C.; Aslanian, A. S.; Lees, J. A.; Yaffe, M. B. p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 2007, 11, 175-89
39. Arora, S.; Bisanz, K. M.; Peralta, L. A.; Basu, G. D.; Choudhary, A.; Tibes, R.; Azorsa, D. O. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells Gynecol. Oncol. 2010, 118, 220-7
40. Zirkin, S.; Davidovich, A.; Don, J. The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM J. Biol. Chem. 2013, 288, 21770-83
41. Qian, K. C.; Wang, L.; Hickey, E. R.; Studts, J.; Barringer, K.; Peng, C.; Kronkaitis, A.; Li, J.; White, A.; Mische, S.; Farmer, B. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase J. Biol. Chem. 2005, 280, 6130-7
42. Brault, L.; Gasser, C.; Bracher, F.; Huber, K.; Knapp, S.; Schwaller, J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers Haematologica 2010, 95, 1004-15
43. Kapelko-Słowik, K.; Urbaniak-Kujda, D.; Wołowiec, D.; Jaźwiec, B.; Dybko, J.; Jakubaszko, J.; Słowik, M.; Kuliczkowski, K. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival Postepy Hig Med. Dosw. 2013, 67, 553-9
44. Fox, C. J.; Hammerman, P. S.; Cinalli, R. M.; Master, S. R.; Chodosh, L. A.; Thompson, C. B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor Genes Dev. 2003, 17, 1841-54
45. Hayakawa, J.; Ohmichi, M.; Kurachi, H.; Kanda, Y.; Hisamoto, K.; Nishio, Y.; Adachi, K.; Tasaka, K.; Kanzaki, T.; Murata, Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin Cancer Res. 2000, 60, 5988-94
46. Marchion, D. C.; Cottrill, H. M.; Xiong, Y.; Chen, N.; Bicaku, E.; Fulp, W. J.; Bansal, N.; Chon, H. S.; Stickles, X. B.; Kamath, S. G.; Hakam, A.; Li, L.; Su, D.; Moreno, C.; Judson, P. L.; Berchuck, A.; Wenham, R. M.; Apte, S. M.; Gonzalez-Bosquet, J.; Bloom, G. C.; Eschrich, S. A.; Sebti, S.; Chen, D. T.; Lancaster, J. M. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival Clin. Cancer Res. 2011, 17, 6356-66